129 related articles for article (PubMed ID: 12810629)
1. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer.
Hefler LA; Grimm C; Ackermann S; Malur S; Radjabi-Rahat AR; Leodolter S; Beckmann MW; Zeillinger R; Koelbl H; Tempfer CB
Cancer Res; 2003 Jun; 63(12):3066-8. PubMed ID: 12810629
[TBL] [Abstract][Full Text] [Related]
2. A common interleukin-6 promoter polymorphism in patients with vulvar cancer.
Grimm C; Six L; Tomovski C; Speiser P; Joura E; Zeillinger R; Sliutz G; Reinthaller A; Hefler LA
J Soc Gynecol Investig; 2005 Dec; 12(8):617-20. PubMed ID: 16198606
[TBL] [Abstract][Full Text] [Related]
3. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma.
Garg R; Wollan M; Galic V; Garcia R; Goff BA; Gray HJ; Swisher E
Gynecol Oncol; 2006 Dec; 103(3):793-6. PubMed ID: 17023036
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
5. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of the interleukin-1 gene cluster and ovarian cancer.
Hefler LA; Ludwig E; Lebrecht A; Zeillinger R; Tong-Cacsire D; Koelbl H; Leodolter S; Tempfer CB
J Soc Gynecol Investig; 2002; 9(6):386-90. PubMed ID: 12445604
[TBL] [Abstract][Full Text] [Related]
8. Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.
Kodama J; Hashimoto I; Seki N; Hongo A; Yoshinouchi M; Okuda H; Kudo T
Anticancer Res; 2001; 21(4B):2983-7. PubMed ID: 11712798
[TBL] [Abstract][Full Text] [Related]
9. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 receptor antagonist gene polymorphism in epithelial ovarian cancer.
Sehouli J; Mustea A; Koensgen D; Lichtenegger W
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1205-8. PubMed ID: 14652282
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
[TBL] [Abstract][Full Text] [Related]
12. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of ovarian cancer associated with endometriosis.
Kumar S; Munkarah A; Arabi H; Bandyopadhyay S; Semaan A; Hayek K; Garg G; Morris R; Ali-Fehmi R
Am J Obstet Gynecol; 2011 Jan; 204(1):63.e1-7. PubMed ID: 21074136
[TBL] [Abstract][Full Text] [Related]
14. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
[TBL] [Abstract][Full Text] [Related]
15. [Survival of patients with ovarian cancer in the Ul'ianovsk Region, 1999-2005].
Antoneeva II
Vopr Onkol; 2007; 53(4):393-5. PubMed ID: 17969399
[No Abstract] [Full Text] [Related]
16. Loss of cables, a novel gene on chromosome 18q, in ovarian cancer.
Dong Q; Kirley S; Rueda B; Zhao C; Zukerberg L; Oliva E
Mod Pathol; 2003 Sep; 16(9):863-8. PubMed ID: 13679449
[TBL] [Abstract][Full Text] [Related]
17. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer is a heterogeneous disease.
Wang V; Li C; Lin M; Welch W; Bell D; Wong YF; Berkowitz R; Mok SC; Bandera CA
Cancer Genet Cytogenet; 2005 Sep; 161(2):170-3. PubMed ID: 16102589
[TBL] [Abstract][Full Text] [Related]
19. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
20. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
Shigemasa K; Tian X; Gu L; Tanimoto H; Underwood LJ; O'Brien TJ; Ohama K
Oncol Rep; 2004 Jun; 11(6):1153-9. PubMed ID: 15138549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
